Gitlab Inc vs TransMedics Group Inc — how do they compare? Gitlab Inc trades at $31.44 (market cap $5.54B), while TransMedics Group Inc trades at $77.86 (market cap $2.61B). The key difference: Gitlab Inc is far larger — about 2.1× TransMedics Group Inc's market cap, and Gitlab Inc is trading nearer its 52-week high, TransMedics Group Inc nearer its low. Which is the better fit depends on your goals.
| GTLB | TMDX | |
|---|---|---|
Market Cap | $5.54B | $2.61B |
Sector | Technology | Technology |
52-Week High | $51.04 | $150.42 |
52-Week Low | $19.42 | $61.99 |
Enterprise Value | $4.29B | $3.01B |
Signals from Pluang's Aura AI — not financial advice
GitLab (GTLB) trades at $32.98, down 1.46% on the day, with a bullish technical signal from moving averages and a consensus analyst price target of $32.50. The company reported strong revenue growth to $759 million in 2025, though it remains unprofitable with a net margin of -2.49%. Recent news highlights its leadership in DevSecOps and AI-driven software development, including a fourth consecutive Leader recognition in Gartner's Magic Quadrant as of June 2026.
Outlook: GitLab's strategic position in the AI and DevSecOps space offers growth potential, but high valuation multiples and persistent losses pose risks. Investor sentiment is mixed, with analysts divided between buy and hold ratings. Key catalysts include execution on profitability and enterprise adoption of AI tools, while competitive pressures and macroeconomic headwinds remain concerns.
No Aura AI signal available yet.
Trailing returns across standard periods
GitLab Inc operates on an all-remote model. The company is a technology company whose primary offering is GitLab, a complete DevOps platform delivered as a single application. GitLab is used by a wide range of organizations. The company also provides related training and professional services. GitLab is offered on both self-managed and software-as-a-service (SaaS) models. The principal markets for GitLab are currently located in the United States, Europe, and Asia Pacific. The company is focused on accelerating innovation and broadening the distribution of its platform to companies across the world.
Read more on GTLB →TransMedics is a pioneering medical technology company that is disrupting the organ transplant market with its Organ Care System (OCS™). By replacing traditional cold storage with portable warm perfusion, the OCS maintains donor organs in a near-physiologic state, allowing for continuous assessment and optimization. Through its National OCS Program (NOP™), TransMedics provides an end-to-end clinical and logistics solution, including a dedicated aviation fleet, to maximize the utilization of donor organs and improve patient outcomes.
Read more on TMDX →